NYMXFOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
NYMOX PHARMACEUTICAL CORP
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Sep 14, 2026
$0.04+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
NYMOX PHARMACEUTICAL CORP revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | $0 | $0 | $0 | – | – | – | – | – | – | – | – | – |
| Europe [Member] | $0 | $0 | $0 | – | – | – | – | – | – | – | – | – |
| Canada [Member] | $0 | $0 | $0 | – | – | – | – | – | – | – | – | – |
| United States [Member] | – | $0 | $0 | $0 | $0 | $3.00K | $91.00K | $276.00K | $197.00K | $232.00K | – | – |
| Europe [Member] | – | $0 | $0 | $0 | $0 | $2.00K | $24.00K | $22.00K | $21.00K | $51.00K | – | – |
| Canada [Member] | – | $0 | $0 | $0 | $0 | $0 | $1.00K | $1.00K | $5.00K | – | – | – |
From the segment and revenue-disaggregation notes of Nymox Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.